SCORED Trial (Sotagliflozin) Risk Index Calculator
- SCORED Trial (Sotagliflozin) Risk Index — explanation and clinical context
This calculator implements a trial-derived risk estimator based on SCORED trial aggregate results. SCORED enrolled adults with type 2 diabetes and chronic kidney disease and reported a primary composite event rate in the placebo arm of approximately 7.5 events per 100 patient-years (≈7.5% per year) and an estimated hazard ratio of 0.74 for the sotagliflozin arm versus placebo for the primary composite endpoint; the default values in this tool reflect these trial-level numbers. By default the tool uses the trial average baseline risk (7.5%/year) or you may supply your own estimated baseline annual risk (%) to reflect a different patient or population. The treated-event estimate is calculated assuming a constant proportional hazard (treated risk = baseline risk × HR).
Clinical interpretation: this tool provides an estimate of absolute and relative treatment effect for a one-year horizon using SCORED trial HRs. It is not a validated individualized prediction model; personalized risk depends on many patient-level factors not captured here. Use these estimates as transparent, trial-based approximations to inform discussions about expected absolute benefit and NNT when considering sotagliflozin in populations similar to SCORED participants.
Reference:
Bhatt DL, et al. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease (SCORED). NEJM and related SCORED publications; SCORED reported placebo event rate ≈7.5 per 100 patient-years and HR ≈0.74 for the primary composite. For trial details and secondary analyses see SCORED publications and FDA integrated review.
Discussion
No discussions yet. Be the first to comment.
Create Note
Notes are stored privately on your device only. No login required. Nothing is uploaded or shared.